Artificial Oxygen Carriers as Oxygen Therapeutics

点击翻译按钮获取中文摘要

We studied protective effects of three artificial oxygen carries of our own original development as follows;1. Liposome-encapsulated hemoglobin (LEH),2. Nitric-Oxide-Sulfonyl-Polyethyleneglycol-Hemoglobin (SNO-PEG-Hb)3. Per fluorocarbon Compounds (PFC).These artificial oxygen carriers have been tested in animal models of organ ischemia or hypoxic conditions; A. Cerebral infarction, B. Myocardial ischemia, C. Cardiac arrhythmias, D. Cancer Radiation Therapy, E. Wound Healing, F. Human Immune System, G. Skeletal Muscle Ischemia, H. Total Brain Ischemia, I. Human Platelet.On these models, influence or difference on effects of,α) Dose-Response relationship: 10 mL/kg, 2 mL/kg, 0.4 mL/kg, 0.08 mL/kg, 0.016 ml/kgβ) Oxygen Affinity: P50O2=45 mmHg (low) and P5002=10 mmHg (high)γ) Individual Oxygen Carriers: LEH, SNO-PEG-Hb, PFCδ) Prospective Utility in Blood Bank, has been explored and reported.In summary, these artificial oxygen carriers, specifically LEH, have been proved to be protective of organ ischemia (cerebral, myocardial, skeletal muscle, arrhythmia), to facilitate wound healing, and to potentiate cancer radiation therapy at minimal effective doses of 0.08 mL/kg to 2 mL/kg depending on application and oxygen affinity, which is found to be more potent with a higher affinity (P_<50>O_2=10 mmHg). Moreover, LEH proves to be non-immunogenic to human lymphocytes, and no-interferent with human platelets, suggesting a safe, innovative, and effective clinical application once approved for human use.